Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2

Molecular Therapy — Methods & Clinical Development(2021)10.1016/j.omtm.2021.03.003Source: DataRank Database

In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2 is a research paper published in Molecular Therapy — Methods & Clinical Development (2021). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

refseq

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (21)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Collin Kieffer ORCID,Pamela J. Björkman ORCID,Magnus A. G. Hoffmann ORCID

Live enrichment

PubMed:33723514 PMC:PMC7944778

Bill and Melinda Gates Foundation

Grant: OPP1202246

Wellcome Trust

Grant: 102610

Scalable in vitro production of red cells for clinical transfusion.

Wellcome Trust

Grant: 087430

Proof of principle: human embryonic stem cell derived red cell concentrates for clinical transfusion.

Wellcome Trust

goldLicense: cc-by

publisherhttp://www.cell.com/article/S2329050121000437/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2329050121000437?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2329050121000437?httpAccept=text/plain

repositoryhttps://escholarship.org/uc/item/1c76698t

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7944778

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

HIV-1Anti-viral TherapeuticsEngineered Red Blood CellsSars-cov-2570QH573-671Prevention610HematologyQH426-470Infectious DiseasesGood Health and Well BeingGeneticsHIV/AIDSOriginal ArticleInfectionCytologyBiotechnology

Sustainable Development Goals

SDG 3: 3. Good health

In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2

FAIR Checklist

Authors (3)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)